Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET
Company Participants
Paul Goodson – IR
Wenbin Jiang – CEO
William McCombe – CFO
Conference Call Participants
David Westenberg – Piper Sandler
Matthew Sykes – Goldman Sachs
Chad Wiatrowski – TD Cowen
Harrison Parsons – Stephens Inc.
Operator
Thank you for standing by, and good day, everyone. My name is RG, and I will be your conference operator today. At this time, I would like to welcome everyone to the Cytek Biosciences Fourth Quarter and Full Year 2024 Earnings Conference Call. All lines have been placed on mute, to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.
I would now like to turn the call over to Paul Goodson, Head of Investor Relations. Please go ahead.
Paul Goodson
Thank you, operator. Earlier today, Cytek Biosciences released financial results for the quarter and year ended December 31, 2024. If you haven’t received this news release or would like to be added to the company’s distribution list, please send an e-mail to investors@cytekbio.com. A copy of the news release is also available on the Investor Relations section of Cytek’s website at investors.cytekbio.com.
Joining me today from Cytek are Wenbin Jiang, CEO; and Bill McCombe, CFO. Please note that we will be referencing a slide presentation during the call today that has been posted to the Investors section of our corporate website.
As a reminder, we will make statements during this call that are forward-looking statements within the meaning of the federal securities laws, including statements regarding Cytek’s business plans, strategies, opportunities and financial projections. These statements are based on the company’s current expectations and inherently involve significant risks and uncertainties that could cause actual results or events to materially differ from those